High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Breast Cancer

References

• Landis S H, Murray T, Bolden S. Cancer statistics, 1998. CA Cancer J Clinicians 1998; 48: 6–29
   PubMed Web of Science ®Google Scholar
• Henderson I C. Basic principles in the use of adjuvant therapy. Semin Oncol 1990; 17: 40–44
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialist's Collaborative Group. Systemic therapy of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 1: 71–85
   Google Scholar
• Antman KH., Rowlings P A, Vaughan W P. High-dose chemotherapy with autologous hematopoietic stem cell support for breast cancer in North America. J Clin Oncol 1997; 15: 1870–1879
   PubMed Web of Science ®Google Scholar
• National Hospital Discharge Survey for 1990 and 1991. U.S. Department of Health and Human Services. Public Health Service, Center for Disease Control. National Center for Health Statistics. Hospital Care Statistics Branch, Hyattsville, MD
   Google Scholar
• Peters W P, Ross M, Vredenburgh J J. The use of intensive clinic support to permit outpatient autologous bone marrow transplantation for breast cancer. Semin Oncol 1994; 21: 25–31
   PubMed Web of Science ®Google Scholar
• Peters W P, Rogers M C. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer. N Engl J Med 1994; 330: 473–477
   PubMed Web of Science ®Google Scholar
• Gale R P. Progress in acute myeloid leukemia. Ann Intern Med 1984; 101: 702–705
   PubMed Web of Science ®Google Scholar
• Buchner T, Hiddemann W, Loffier G. Improved cure rate by very early intensification combined with prolonged maintenance chemotherapy in patients with acute myeloid leukemia: data from the AML Cooperative Group. Semin Oncol 1991; 28: 76–79
   Google Scholar
• Culbert S J, Shuster J J, Land V J. Remission induction and continuation therapy in children with their first relapse of acute lymphoid leukemia. A Pediatric Oncology Group Study. Cancer 1991; 67: 37–42
   PubMed Web of Science ®Google Scholar
• Kilmo M P, Connors J M. MACOP-B chemotherapy for diffuse large-cell lymphoma. Ann Intern Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Armitage J O, Chesson B D. Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 1988; 6: 1335–1347
   PubMed Web of Science ®Google Scholar
• Armitage J O. The place of third-generation regimens in the treatment of adult aggressive non-Hodgkin's lymphoma. Ann Oncol 1991; 2: 37–41
   PubMed Web of Science ®Google Scholar
• DeVita VT, Jr, Hubbard S M, Young R C. The role of chemotherapy in diffuse aggressive lymphomas. Semin Hematol 1988; 25: 1–10
   Google Scholar
• Diaz P, Cabanillas R. Treatment of non-Hodgkin's lymphoma. Curr Opin Oncol 1991; 3: 830–837
   PubMedGoogle Scholar
• Einhorn L H. Testicular cancer: a model for curable neoplasm. The Richard and Hilda Rosenthal Foundation Award Lecture. Cancer Res 1981; 41: 3275–3280
   PubMed Web of Science ®Google Scholar
• Broun E R, Nichols C R, Kneebone P. Long-term outcome of patients with relapsed and refractory germ tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 1992; 117: 124–128
   PubMed Web of Science ®Google Scholar
• Einhom L H, Williams S D, Loehrer P J. Evaluation of optimal duration of chemotherapy in favorable prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol 1989; 7: 387–391
   PubMed Web of Science ®Google Scholar
• Nichols C R, Tricot G, Williams S D. Dose-intensive chemotherapy in refractory germ cell cancer-a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol 1989; 7: 932–939
   PubMed Web of Science ®Google Scholar
• Einhorn L H. Treatment of testicular cancer: a new and improved model. J Clin Oncol 1990; 8: 1777–1781
   PubMed Web of Science ®Google Scholar
• Iancotti N I, Bosl G J. A review of the management germ cell tumors: evolution of a curative treatment program. Cancer Invest 1990; 8: 173–179
   PubMed Web of Science ®Google Scholar
• Adelstein D J, Sharan V M, Earle A S. Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer. Am J Clin Oncol 1990; 13: 440–447
   PubMed Web of Science ®Google Scholar
• Piver M S. Ovarian carcinoma. A decade of progress. Cancer 1984; 54: 2706–2715
   PubMedGoogle Scholar
• Young R C. Mechanisms to improve chemotherapy effectiveness. Cancer 1990; 65: 815–822
   PubMed Web of Science ®Google Scholar
• DePree N, Wils J. Long-term survival of patients with advanced ovarian carcinoma treated with cisplatin based chemotherapy regimens. Anticancer Res 1989; 9: 1869–1871
   PubMed Web of Science ®Google Scholar
• Stiff P J, Bayer R, Kerger C. High dose chemotherapy with autologous transplantation for persistent, relapsed ovarian cancer: a multivariate analysis of survival for 100 consistently treated patients. J Clin Oncol 1997; 15: 1309–1317
   PubMed Web of Science ®Google Scholar
• Henderson I C, Canellos G P. Cancer of the breast over the past decade. N Engl J Med 1980; 302: 78–90
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 1: 1–15; 71–85
   Google Scholar
• Fisher B, Brown A M, Dimitrov N V. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen non responsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990; 8: 1482–1496
   Google Scholar
• Fisher B, Redmond C, Legault-Poisson S. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990; 8: 1005–1018
   PubMed Web of Science ®Google Scholar
• Henderson I C. Adjuvant systemic therapy: state of the art, 1989. Breast Cancer Res Treat 1989; 15: 3–22
   Google Scholar
• Schabel F M. Animal models as predictive systems. Cancer Chemotherapy: Fundamental and Recent Advances. Year Book Medical Publishers, Chicago 1975; 323
   Google Scholar
• Skipper H E, Schabel F M, Janey R. Experimental evaluation of anti-tumor agents. Cancer Chemother Rep 1961; 35: 1–35
   Google Scholar
• Frei E, Canellos G C. Dose: a critical factor in cancer therapy. Am J Med 1980; 69: 585–594
   PubMed Web of Science ®Google Scholar
• Peters W P, Dansey R. New concepts in the treatment of breast cancer using high-dose chemotherapy. Cancer Chemother Pharmacol 1997; 40: S88–93
   PubMed Web of Science ®Google Scholar
• Goldie J H, Coldman A J. A mathematic model for relating the drug sensitivity of tumors to the spontaneous mutation rate. Cancer Treat Rep 1979; 63: 1727–1733
   PubMedGoogle Scholar
• Priestman T, Baum M, Jones V. Treatment and survival in advanced breast cancer. B Med J, 2: 1673–1674
   PubMed Web of Science ®Google Scholar
• Powell T G, Sniff I E, Ford H T. Failure of chemotherapy to prolong survival in a group of patients with metastatic breast cancer. Lancet 1980; 1: 580–582
   PubMed Web of Science ®Google Scholar
• Frei E. Pharmacologic strategies for high-dose chemotherapy. High Dose Cancer Therapy: Pharmacology, Hematopoietisis, Stem Cells, JO Armitage. Williams & Wilkins, Baltimore 1992; 3–13
   Google Scholar
• Schabel FM, Jr, Skipper H E, Trader M W. Establishment of cross-resistance profiles for new agents. Cancer Treat Rep 1983; 57: 905–922
   Google Scholar
• Schabel F M, Trader M W, Laster W R. Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother 1978; 23: 200–215
   PubMedGoogle Scholar
• Jones R B, Shpall E J, Ross M. High-dose carboplatin, cyclophosphamide, and BCNU with autologous bone marrow support: excessive hepatic toxicity. Cancer Chemother Pharmacol 1990; 26: 155–156
   PubMed Web of Science ®Google Scholar
• Egorin M J, Cohen B E, Herzig R H. Human plasma pharmacokinetics and urinary excretion of thiotepa and its metabolites in patients receiving high-dose thiotepa therapy. Advances in Cancer Chemotherapy: High-dose Thiotepa and Autologous Marrow Transplantation, GP Herzig. Park Row Publishers, New York 1987
   Google Scholar
• Thomas E D, Storb R, Clift R A. Bone marrow transplantation. N Engl J Med 1975; 292: 832–895
   PubMed Web of Science ®Google Scholar
• Thomas E D, Buckner C D, Clift R A. Marrow transplantation for acute nonlymphoblastic leukemia in first remission. N Engl J Med 1979; 301: 597–599
   PubMed Web of Science ®Google Scholar
• Hryniuk W, Bush H. The importance of dose intensity in chemotherapy for metastatic breast cancer. J Clin Oncol 1984; 2: 1281–1288
   PubMed Web of Science ®Google Scholar
• Henderson I C, Hayes D F, Gelman R. Dose response in the treatment of breast cancer. J Clin Oncol 1988; 6: 1501–1515
   PubMed Web of Science ®Google Scholar
• Peters W P. High-dose chemotherapy and autologous bone marrow support for breast cancer. Important Advances in Oncology, VT DeVita, S Hellman, SA Rosenberg. J.B. Lippincott, Philadelphia 1991; 135–150
   Google Scholar
• Tannock I, Boyd N, DeBoer G. A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 1988; 6: 1377–1387
   PubMed Web of Science ®Google Scholar
• Perkins J B, Fields K K, Elfenbein G J. Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. Semin Oncol 1995; 22(3 Suppl 7)5–8
   PubMed Web of Science ®Google Scholar
• Winer E, Berry D, Duggan D. Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer—results from CALGB 9342. Proc Am Soc Clin Oncol 1998; 17: 101a, abstract
   Google Scholar
• Henderson I C. Chemotherapy for advanced disease. Breast Diseases, JR Harris. J.B. Lippincott, Philadelphia 1987; 428–479
   Google Scholar
• Peters W P, Eder J P, Schryber S. High-dose combination alkylating agents with autologous bone marrow support: a phase I trial. J Clin Oncol 1986; 4: 646–654
   PubMed Web of Science ®Google Scholar
• Eder J P, Antman, Peters W P. High dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986; 4: 1592–1597
   PubMed Web of Science ®Google Scholar
• Antman K, Bearman S I, Davidson. Dose intensive therapy in breast cancer: current status. New Strategies in Bone Marrow Transplantation, RP Gale, RE Champlin. Alan R. Liss, New York 1990; 423–436
   Google Scholar
• Peters W P, Shpall E J, Jones R B. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 1988; 6: 1368–1376
   PubMed Web of Science ®Google Scholar
• Peters W P. Autologous bone marrow transplantation for breast cancer. Bone Marrow Transplantation, SJ Forman, KG Blume, ED Thomas. Blackwell Scientific Publications., Cambridge 1994; 789–801
   Google Scholar
• Gisselbrecht C, LePage E, Extra J. Inflammatory and metastatic breast cancer: cyclophosphamide and total body irradiation (TBI) with autologous bone marrow transplantation (ABMT). Autologous Bone Marrow Transplantation. Procedeings of the Fourth International Symposium, K Dicke, G Spitzer, S Jagannath. M.D. Anderson Cancer Center Press, Houston 1989; 363–367
   Google Scholar
• Peters W P, Shpall E J, Jones R B. High-dose combination cyclophosphamide, cisplatin, and carmustine with bone marrow support as initial treatment for metastatic breast cancer: three to six year follow-up. Proc Am Soc Clin Oncol 1990; 9: 10
   Google Scholar
• Moonneier J A, Williams S F, Kaminer L S. High dose trialkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies. J Natl Cancer Inst 1990; 82: 29–34
   PubMed Web of Science ®Google Scholar
• Kennedy M J, Beveridge R A, Rowley S D. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst 1991; 83: 920–926
   PubMed Web of Science ®Google Scholar
• Eddy D M. Review article. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol, 10: 657–670
   PubMed Web of Science ®Google Scholar
• Antman K, Ayash Elias L. A. A phase II study of high dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measureable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1992; 10: 102–110
   PubMed Web of Science ®Google Scholar
• Williams S F, Gilewski T, Mick R. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol 1992; 10: 1743–1747
   PubMed Web of Science ®Google Scholar
• Klumpp T R, Mangan K F, Glenn L D. Phase II pilot study of high-dose busulfan and CY followed gy autologous BM or peripheral blood stem cell transplantation in patients with advanced chemosensitive breast cancer. Bone Marrow Transplant 1993; 11: 337–339
   PubMed Web of Science ®Google Scholar
• Myers S E, Mick R, Williams S F. High-dose chemotherapy with autologous stem cell rescue in women with metastatic breast cancer with involved bone marrow: a role for peripheral blood progenitor transplant. Bone Marrow Transplant 1994; 13: 449–454
   PubMed Web of Science ®Google Scholar
• Lazarus H M, Gray R., Ciobanu N. A phase I trial of high-dose melphalan, high-dose etoposide, and autologous bone marrow re-infusion in solid tumors: an Eastern Cooperative Oncology Group (ECOG) study. Bone Marrow Transplant 1994; 14: 443–448
   PubMed Web of Science ®Google Scholar
• Weaver C H, Bensinger W I, Appelbaum F R. Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone Marrow Transplant 1994; 14: 813–819
   PubMed Web of Science ®Google Scholar
• Somlo G, Doroshow J H, Forman S J. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancer. Cancer 1994; 73: 1678–1685
   PubMed Web of Science ®Google Scholar
• Somlo G, Doroshow J H, Forman S J. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer 1994; 73: 125–134
   PubMed Web of Science ®Google Scholar
• Vaughan W P, Reed E C, Edwards B. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer. Bone Marrow Transplant 1994; 13: 619–624
   PubMed Web of Science ®Google Scholar
• Saez R A, Selby G B, Slease R B. Autologous bone marrow transplantation for metastatic breast cancer. J Okla State Med Assoc 1994; 87: 405–410
   PubMedGoogle Scholar
• Fields K K, Elfenbein G J, Lazarus H M. Maximum tolerated doses of ifosfamide, carboplatin, and etoposide given over six days followed by autolobous stem cell rescue: toxicity profile. J Clin Oncol 1995; 13: 323–332
   PubMed Web of Science ®Google Scholar
• Kalaycioglu M E, Lichtin A E, Andresen S W. High-dose busulfan and cyclophosphamide followed by autologous bone marrow transplantation and/or peripheral blood progenitor cell rescue for metastatic breast cancer. Am J Clin Oncol 1994; 18: 491–494
   Web of Science ®Google Scholar
• Spitzer T R, Cirenza E, McAfee S. Phase I-II trial of high-dose cyclophosphamide, carboplatin and autologous bone marrow or peripheral blood stem cell rescue. Bone Marrow Transplant 1995; 15: 537–542
   PubMed Web of Science ®Google Scholar
• Gisselbrecht C, Extra J M, Lotz J P. Cyclophosphamide/mitoxantrone/melphalan (CMA) regimen prior to autologous bone marrow transplantation (ABMT) in metastatic breast cancer. Bone Marrow Transplant 1996; 18: 857–863
   PubMed Web of Science ®Google Scholar
• DeMagalhaes-Silverrnan M, Rybka W B, Lembersky B. High-dose cyclophosphamide, carboplatin. and etoposide with autologous stem cell rescue in patients with breast cancer. Am J Clin Oncol 1996; 19: 169–173
   PubMed Web of Science ®Google Scholar
• Stemmer S M, Cagnoni P J, Shpall E J. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 1996; 14: 1463–1472
   PubMed Web of Science ®Google Scholar
• Demirer T, Buckner C D, Appelbaum F R. High-dose busulfan and cyclophosphamide followed by autologous transplantation in patients with advanced breast cancer. Bone Marrow Transplant 1996; 17: 769–774
   PubMed Web of Science ®Google Scholar
• De Vries E G, Rodenhuis S, Schouten H C. Phase II study of intensive chemotherapy with autologous bone marrow transplantation in patients in complete remission of disseminated breast cancer. Breast Cancer Res Treat 1996; 39: 307–313
   PubMed Web of Science ®Google Scholar
• Perkins J B, Effenbein G J, Fields K K. Analysis of dose-response relationships in the setting of high-dose ifosfamide. carboplatin, and etoposide and autologous hematopoietic stem cell transplantation: implications for the treatment of patients with advanced breast cancer. Semin Oncol 1996; 23: 42–46
   PubMed Web of Science ®Google Scholar
• Bezwoda WR, Seymour L, Dansey R D. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483–2489
   PubMed Web of Science ®Google Scholar
• Peters W P, Jones R B, Vredenburgh J. A large, prospective, randomized trial of high-dose combination alkylating agent (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Am Soc Clin Oncol 1996; 15: 149a
   Google Scholar
• Peters W P, Jones R B, Vredenburgh J. A large, prospective, randomized trial of high-dose combination alkylating agent (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Cancer Res Treat 1996; 37: 35
   Google Scholar
• Lazarus H M. Hematopoietic progenitor cell transplantation in breast cancer: current status and future directions. Cancer Invest 1998; 16: 102–126
   PubMed Web of Science ®Google Scholar
• Rohman Z U, Frye D K, Buzdar A U. Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer. J Clin Oncol 1997; 15: 3171–3177
   PubMed Web of Science ®Google Scholar
• Zambetti M, Valugussa P, Bonadonna G. Eight-year results with adjuvant intravenous CMF in nodenegative (N-) and estrogen receptor negative (ER-) breast cancer. Proc Am Soc Clin Oncol 1992; 11: 69a
   Google Scholar
• Budman D R, Wood W, Henderson I C. Initial findings of CALGB 8541: a dose and dose intensity trial of cyclophosphamide (C), doxorubicin (A), and 5-fluorourcal (F) as adjuvant treatment of stage II, node + female breast cancer. Proc Am Soc Clin Oncol 1992; 11: 29a
   Google Scholar
• Muss HB., Thor A D, Berry D A. cerbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994; 330: 1260–1266
   PubMed Web of Science ®Google Scholar
• Bhardwaj S, Holland J F, Norton L. An intensive sequenced adjuvant chemotherapy regimen for breast cancer. Cancer Invest 1993; 11: 6–9
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S., Wickerham D L. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997; 15: 1858–1869
   PubMed Web of Science ®Google Scholar
• Henderson I, Berry C., Demetri D. G. Improved disease free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am Soc Clin Oncol 1998; 17: 101a
   Google Scholar
• Robert N J, Gray R, Gelber R D. Node positive (N+) breast cancer: which patients are at high risk. Proc Am Soc Clin Oncol 1991; 10: 111a
   Google Scholar
• Peters W P, Ross M, Vredenburgh J J. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993; 11: 1132–1143
   PubMed Web of Science ®Google Scholar
• Gianni A M, Siena S, Bregni M. Growth factor supported high-dose sequential (HDS) adjuvant chemotherapy in breast cancer with ≥ 10 positive nodes. Proc Am Soc Clin Oncol 1992; 11: 60
   Google Scholar
• Peters W P, Dansey R, Klein J. High-dose chemotherapy for high-risk primary breast cancer. Adjuvant Therapy of Cancer VIII, SE Salmon. Lippincott-Raven, Philadelphia 1997; 117–122
   Google Scholar
• Gianni A M, Siena S, Bregni M. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997; 15: 2312–2321
   PubMed Web of Science ®Google Scholar
• Razis E D, Samonis G, Cook P. TMJ: a well-tolerated high-dose regimen for the adjuvant chemotherapy of high risk breast cancer. J Med 1994; 25: 241–250
   PubMedGoogle Scholar
• Peters W P, Fay J W, Holland H K. Autologous bone marrow transplantation as adjuvant therapy in primary breast cancer: the American experience. Bone Marrow Transplant 1995; 15: S254–S259, (Suppl 1)
   Google Scholar
• Holland H K, Dix S P, Geller R B. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care. J Clin Oncol 1996; 14: 1156–1164
   PubMed Web of Science ®Google Scholar
• Thomas J, Perez- F., Carrion R, Escudero A. Results of a pilot study of 40 patients using high-dose therapy with hematopoetic rescue after standard-dose adjuvant therapy for high-risk breast cancer. Bone Marrow Transplant 1997; 19: 331–336
   PubMed Web of Science ®Google Scholar
• Rodenhuis S, Van der Wall Richel D J. A randomized trial of high-dose chemotherapy and hematopoietic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. Proc Am Soc Clin Oncol 1998; 17: 123a
   Google Scholar
• Rodenhuis S, Richel D, Van der Wall E. Randomized trial of high-dose chemotherapy and haematopoietic progenitor-cell support in operable breast cancer with extensive axillary lymphnode involvement. Lancet 1998; 352: 515–521
   PubMed Web of Science ®Google Scholar
• Hryniuk Frei W. E, III, Wright F A. A single scale for comparing dose-intensity of all chemotherapy regimens in breast cancer: summation dose-intensity. J Clin Oncol 1998; 16: 137–3147
   Google Scholar
• Garcia-Carbonero R, Hidalgo M, Paz-Ares L. Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J Clin Oncol 1997; 15: 3178–3184
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N, Buzdar A U, Chemplin R. Lack of efficacy of adjuvant high-dose tandem combination chemotherapy for high risk primary breast cancer—a randomized trial. Proc Am Soc Clin Oncol 1998; 17: 123a
   Google Scholar
• Pustztai L, Hortabagyi G N. Discouraging news for high-dose chemotherapy in high-risk breast cancer. Lancet 1998; 352: 501–502
   PubMed Web of Science ®Google Scholar
• Vahdat L, Antman K. High-dose chemotherapy with autologous stem cell support for breast cancer. Curr Opin Hematol 1997; 4: 381–389
   PubMedGoogle Scholar
• Viens P, Penault-Llorca F, Jacquemier J. High-dose chemotherapy and hematopoietic stem cell transplantation for inflammatory breast cancer: pathologic response and outcome. Bone Marrow Transplant 1998; 21: 249–254
   PubMed Web of Science ®Google Scholar
• Cagnoni P J, Nieto Y, Shpall E J. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. J Clin Oncol 1998; 16: 1661–1668
   PubMed Web of Science ®Google Scholar
• Miller A, Khosla P, Lynch J. Durable remission of locally advanced breast cancer with multimodality management. Med Oncol 1998; 15: 89–95
   PubMed Web of Science ®Google Scholar
• Kennedy M J, Vogelsang G B, Jones R J. Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-ver-sus-host disease in woman undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 1994; 12: 249–257
   PubMed Web of Science ®Google Scholar
• Margolin K A, Wright C, Forman S J. Autologous bone marrow purging by in situ IL-2 activations of endogenous killer cells. Leukemia 1997; 11: 723–728
   PubMed Web of Science ®Google Scholar
• Baynes R D, Wood G W, Skikne B S. Combining dose intensive chemotherapy with specific adoptive immunotherapy in metastic breast cancer. Breast Cancer Res Treat 1997; 46: 68, 270a
   Google Scholar
• Eibl B, Schwaighofer H, Nachbaur D. Evidence for a gratt-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 1996; 88: 1501–1508
   PubMed Web of Science ®Google Scholar
• Ueno N T, Rondon G, Mirza N Q. Allogeneic peripheral blood progenitor cell transplantation for poor risk patients with metastatic breast cancer. J Clin Oncol 1998; 16: 986–993
   PubMed Web of Science ®Google Scholar
• Or R, Ackerstein A, Nagler A. Allogeneic cell-mediated immunotherapy for breast cancer after autologous stem cell transplantation: a clinical pilot study. Cytokines Cell Mol Ther 1998; 1: 1–6
   Google Scholar
• Winer E, Lindley C, Hardee M. Quality of life (QL) assessment in patients with breast cancer surviving 12 months or more following high dose chemotherapy with autologous bone marrow transplant (HDCABMT). Proc Am Soc Clin Oncol 1 1992; 1: 383a
   Google Scholar
• Peters W P, Kurtzberg J, Romber G. Comparative effects of G-CSF and GM-CSF on primary peripheral, blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–1719
   PubMed Web of Science ®Google Scholar
• Hann D M, Jacobsen P B, Martin S C. Quality of life following bone marrow transplantation for breast cancer: a comparative study. Bone Marrow Transplant 1997; 19: 257–264
   PubMed Web of Science ®Google Scholar
• Hann D M, Jacobsen P B, Martin S C. Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer. Support Care Cancer 1997; 5: 44–52
   PubMed Web of Science ®Google Scholar
• Ahles T A, Tope D M, Furstenberg C. psychologic and neu-ropsychologic impact of autologous bone marrow transplantation. J Clin Oncol 1996; 14: 1457–1462
   PubMed Web of Science ®Google Scholar
• McQuellon R P, Craven B, Russell G B. Quality of life in breast cancer patients before and after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1579–1584
   Google Scholar
• Stone R M, Neuberg D, Saiffer R. Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkins lymphoma. J Clin Oncol 1994; 12: 2535–2542
   PubMed Web of Science ®Google Scholar
• Darrington D L, Vose J M, Anderson J R. Incidence and characterization of secondary myelodysplastic syndrome following high-dose chemoradiotherapy and autologous stem-cell transplantation from lymphoid malignancies. J Clin Oncol 1994; 12: 2527–2534
   PubMed Web of Science ®Google Scholar
• Schwartzberg L S, Birch R, West W H. Sequential treatment including high-dose chemotherapy with peripheral blood stem cell support in patients with high-risk stage II-1II breast cancer. Am J Clin Oncol 1998; 21: 523–531
   PubMed Web of Science ®Google Scholar
• Laughlin M, McGaughey D S, Crews J R. Secondary myelodysplasia and acute leukemia in breast cancer patients with autologous bone narrow transplant. J Clin Oncol 1998; 16: 1008–1012
   PubMed Web of Science ®Google Scholar
• Hillner B E, Smith T J, Desch C E. Efficacy and cost effectiveness of autologous bone marrow transplantation in metastatic breast cancer-estimates using decision analysis while awaiting clinical trial results. JAMA 1992; 267: 2055–2061
   PubMed Web of Science ®Google Scholar
• Lawless G D. Cost-effectiveness of autologous bone marrow transplantation. Am. J Health Syst Pharm 1995; 52: S11–14
   PubMedGoogle Scholar